Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) a...
Main Authors: | Sodiomon B. Sirima, Alphonse Ouedraogo, Nouhoun Barry, Mohamadou Siribie, Alfred Tiono, Issa Nébié, Amadou Konaté, Gloria Damoaliga Berges, Amidou Diarra, Moussa Ouedraogo, Edith C. Bougouma, Issiaka Soulama, Alimatou Hema, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Kathleen Tracy, Leslie P. Jamka, Jennifer J. Oshinsky, Marcela F. Pasetti, Kathleen M. Neuzil, Matthew B. Laurens |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221004616 |
Similar Items
-
Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso
by: Sodiomon B. Sirima, et al.
Published: (2021-01-01) -
Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics
by: Andrea Haekyung Haselbeck, et al.
Published: (2021-03-01) -
Typhoid vaccines. Historical aspects of typhoid vaccine development, and currently available products
by: M. V. Abramtseva, et al.
Published: (2021-07-01) -
Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design
by: Yi-An Yang, et al.
Published: (2018-07-01) -
Barriers to typhoid fever vaccine access in endemic countries
by: Khan MI, et al.
Published: (2017-03-01)